70. Spinal stenosis Clinical trials / Disease details
Clinical trials : 96 / Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04066296 (ClinicalTrials.gov) | September 2021 | 3/7/2019 | Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine | A Double Blinded Randomized Control Trial in Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine | Lumbar Spinal Stenosis | Drug: Liposomal bupivacaine | University of Colorado, Denver | NULL | Not yet recruiting | 18 Years | N/A | All | 100 | Phase 2 | NULL |
2 | NCT03745040 (ClinicalTrials.gov) | January 26, 2019 | 5/11/2018 | Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion | Does Liposomal Bupivacaine Improve Postoperative Pain Control After One Level Posterior Spinal Fusion With Instrumentation | Lumbar Spinal Stenosis;Lumbar Disc Herniation;Lumbar Disc Disease;Lumbar Spondylolisthesis | Drug: Liposomal bupivacaine | Allina Health System | Twin Cities Spine Center | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States |